Skip to main content
All Posts By

admin

midamerica-healthcare-venture-forum-2014-logo

Mayo’s James A. Rogers: It’s a great time for startups

By News Archive

midamerica-healthcare-venture-forum-2014-logo

MidAmerica Healthcare Venture Forum, to take place April 22-23 in Chicago, unites active investors with corporate business development executives to facilitate investment opportunities with promising Mid-America based startups.

The event showcases emerging innovation and technology dealflow originating in the Midwest, and has earned the reputation as the premier healthcare investing conference.

Read More
NewImage

Job Opportunity: Senior Business Development Specialist, Grade 27 – Montgomery County

By News Archive

NewImage

The Montgomery County Department of Economic Development is looking for a senior level professional to formulate and implement the County’s economic development strategy related to the growth of the life sciences and health IT industry sectors and to provide policy advice on technology issues in these strategic sectors. The position will foster partnerships and manage projects designed to attract new companies to the County, to enhance the presence of companies in these sectors within the County and to foster a pipeline of new companies in these sectors.

This position will evaluate and make recommendations on the technology policy issues relevant to Montgomery County, and implement creative programs that will expand the County’s technological presence in the global marketplace.   This position affects the County’s economic well-being through the number of additional jobs created, number of companies established, capital raised, and commercial space occupied through new company attraction, retention and growth of existing companies, and a pipeline of startups. The candidate will work collaboratively with DED teammates to build the capabilities and competencies of the Department.

Read More
nsf-national-science-foundation-logo

Cultivating Cultures for Ethical STEM (CCE STEM)

By News Archive

nsf-national-science-foundation-logo

Cultivating Cultures for Ethical STEM (CCE STEM) funds research projects that identify factors that are effacacious in the formation of ethical STEM researchers in all the fields of science and engineering that NSF supports. CCE STEM solicits proposals for research that explores the following: ‘What constitutes ethical STEM research and practice? Which cultural and institutional contexts promote ethical STEM research and practice and why?’ Factors one might consider include: honor codes, professional ethics codes and licensing requirements, an ethic of service and/or service learning, life-long learning requirements, curricula or memberships in organizations (e.g. Engineers without Borders) that stress social responsibility and humanitarian goals, institutions that serve under-represented groups, institutions where academic and research integrity are cultivated at multiple levels, institutions that cultivate ethics across the curriculum, or programs that promote group work, or do not grade. Do certain labs have a ‘culture of academic integrity’? What practices contribute to the establishment and maintenance of ethical cultures and how can these practices be transferred, extended to, and integrated into other research and learning settings?

Read More
sebelius-kathleen-hhs

The Overlooked Influence of Kathleen Sebelius – Scientific American

By News Archive

sebelius-kathleen-hhs

When Kathleen Sebelius took the helm of one of the largest civilian departments in the federal government, the first thorny issue on her desk was responding to the H1N1 flu virus, a new pandemic flu strain that seemed to target otherwise healthy young people. After less than week on the job her first public speech focused on how the Department of Health and Human Services (HHS), which oversees the Centers for Disease Control and Prevention and Food and Drug Administration, was responding to the public health emergency. She released millions of antiviral drugs from the national stockpile and warned against fake flu cures while calling for continual investment into research to stay ahead of future flu outbreaks. Talks about women’s and children’s health, obesity and AIDS soon followed.

Read More
emergent logo

Emergent BioSolutions Successfully Completes Pivotal Clinical Study to Support Expanded Indication for BioThrax – MarketWatch

By News Archive

emergent-logo

Emergent BioSolutions Inc. today announced successful completion of the last licensure-enabling study in its BioThrax® (Anthrax Vaccine Adsorbed) Post-Exposure Prophylaxis (PEP) program. This clinical study, also known as the non-interference study, was designed to evaluate the pharmacokinetic profile of the antimicrobial ciprofloxacin when administered prior to and following the administration of a three-dose series of BioThrax. It was also designed to evaluate the immune response to BioThrax when administered with or without ciprofloxacin. The primary endpoints were the ratio of the maximum concentration (Cmax) and area under the curve (AUC) for ciprofloxacin and the secondary endpoint was the ratio of the geometric mean titer of the antibody response to BioThrax two weeks following the last dose. The study met the prospectively defined success criteria for both the primary and secondary endpoints. Data from this study show no interaction between ciprofloxacin and BioThrax.

Emergent has submitted the final clinical study report to the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Food and Drug Administration (FDA). Results from this study will be used to support a supplemental Biologics License Application (sBLA) seeking licensure of a PEP indication for BioThrax to be used in combination with antibiotics in people with suspected or confirmed exposure to anthrax spores. BioThrax is currently licensed for a pre-exposure prophylaxis indication only.

Read More
Qiagen

Qiagen to depart old Digene HQ, expand two other Maryland campuses – Washington Business Journal

By News Archive

Qiagen

Qiagen NV, the Dutch diagnostics technology company that bought  Gaithersburg-based Digene for $1.6 billion in 2007, is preparing to clear out of Digene’s old offices and move staff to an expanded Germantown headquarters.

The move has  been in the works for years, but Qiagen can finally push forward following recent FDA clearance of its 270,000-square-foot Germantown site for manufacturing the company’s human papillomavirus (HPV) test. That HPV test, developed by Digene, was the impetus for the 2007 acquisition.

Read More
pecht-umd-image

2014 UMD Corporate Connector of the Year Announced – University of Maryland Division of Research

By News Archive

pecht-umd-image

The University of Maryland announced today that the 2014 University of Maryland Corporate Connector of the Year Award recipient will be Dr. Michael Pecht and the UMD Center for Advanced Life Cycle Engineering (CALCE).  The UMD Corporate Connect Council annually recognizes a University of Maryland researcher, staff or unit that has achieved significant engagement with the private sector in corporate research, philanthropy, or student support.

Pecht will receive his award as part of the University’s Celebration of Innovation and Partnerships on Tuesday, April 29, 2014 at University House in College Park, Maryland. Pecht’s engagement with the private sector has played a large role in making UMD CALCE, headquartered at the College Park campus, the world’s largest manufacturing consortium in electronic parts reliability engineering, accelerated testing, and supply chain management. Over 150 corporations, federal labs, universities and leading international research centers are members. 

Read More

93rd Edition – April 15, 2014

By BHI Weekly Newsletter Archives






You’re receiving this newsletter because of your interest in BioHealth Innovation
Having trouble viewing this email? View it in your browser.





Follow us on YouTube Follow us on Twitter





University System of Maryland secures final legislative victories – The Diamondback

University System of Maryland

With a budget bill passed this weekend and the University System of Maryland successfully lobbying for limited cuts to its state funding, the final day of the state’s legislative session was less intense for the higher education lobby.

The most significant bills for this university and the university system received support in both chambers of the legislature and passed with little controversy.

But for what amounted to a quiet day, the university system secured significant victories, with measures that use university resources to spur economic development and a state grant program aimed at attracting talented faculty to state universities passing one right after the other on the morning of sine die.

back to top Back to top



GlycoMimetics Announces Presentation of Data on Rivipansel (GMI-1070) in Combination with Current FDA-Approved Treatment for Sickle Cell Disease – WSJ.com

glycomimetics-logo

GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that data for its lead clinical drug candidate, rivipansel (GMI-1070), was highlighted via one oral presentation and one poster at the 8th Annual Sickle Cell Disease Research and Educational Symposium and 37th National Sickle Cell Disease Scientific Meeting, held April 11-14, 2014, at the InterContinental Miami.

Rivipansel is in clinical trials as a potential therapy for the treatment of vaso-occlusive crisis (VOC) in people with sickle cell disease. It has previously received both Orphan Drug and Fast Track status for the treatment of VOC from the U.S. Food & Drug Administration (FDA), and Orphan Product status in the European Union. GlycoMimetics is developing rivipansel in collaboration with Pfizer, Inc.

back to top Back to top



11 Awesome Startup Ideas Launched in Just 36 Hours at UMD – InTheCapital

bitcamp-logo

A group of University of Maryland undergraduates put together a spectacular hackathon this weekend, attracting more than 750 college students from across the country to take part in the 36-hour long event. The hackathon, which went by the name of Bitcamp, lasted from April 4-6 in Cole Field House on school grounds, providing students with the opportunity to collaborate with fellow innovators in creating brilliant new hardware and applications for mobile devices, computers or the Web.

back to top Back to top



QIAGEN Adds Promising New Biomarker to Pipeline of Personalized Healthcare Assays to Improve Diagnosis of Blood Disorders – MarketWatch

Qiagen

QIAGEN N.V. today announced it has acquired an exclusive worldwide license to the biomarker calreticulin (CALR), whose recently discovered mutations are found in an estimated 15% of cases of myeloproliferative neoplasms (MPNs), a group of blood disorders. QIAGEN licensed the technology from CeMM Vienna, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, whose scientists led a team that discovered the presence of mutations of the CALR protein in MPNs. QIAGEN plans to develop a molecular diagnostic test for the CALR mutations to offer each patient a clearer prognostic profile and to guide disease management. Development of a CALR diagnostic test is expected to be highly complementary to QIAGEN’s kits for a key mutation of the Janus kinase 2 (JAK2) gene.

Myeloproliferative neoplasms, a group of blood disorders involving overproduction of blood cells, are chronic diseases that can lead to several complications including thrombosis (blood clots) and in some cases difficult-to-treat acute leukemia. QIAGEN already has an exclusive license for the JAK2 V617F mutation, which is present in about 75% of patients with MPNs. According to an article published in the New England Journal of Medicine in December 2013 by the CeMM team led by Robert Kralovics, patients with CALR mutations suffer from a milder form of the disease than those with the JAK2V617F mutation, including a lower risk of thrombosis and a higher survival rate.

back to top Back to top



Federal Labs & Industry Partners Aim to Accelerate Innovation for Economic Impact at the 2014 FLC National Meeting – PR.com

flc-logo

This year has been charted with the unfolding of several White House technology initiatives that involve leveraging the groundbreaking work of the nation’s federal laboratories. In 1986, the Federal Laboratory Consortium for Technology Transfer (FLC) was mandated to pursue these initiatives by facilitating the movement of technologies from labs to the marketplace, strengthening research and development by streamlining technology transfer (T2) procedures, and increasing industry partnerships and collaborations. And, given the theme of this year’s FLC national meeting, “Accelerating Innovation for Economic Impact,” coupled with its nearby capital setting at the North Bethesda Marriott in Rockville, Maryland, this year is no exception.

back to top Back to top



DC I-Corps Now Accepting Applications for Spring Cohort

bhi-logo
dc-i-corps-logo

DC I-Corps, in partnership with BioHealth Innovation, Inc., has developed a new, NSF-supported program designed to foster, grow and nurture the life science innovation ecosystem in the Mid-Atlantic Region and is now accepting applications for its spring cohort, beginning on May 12th. Applications will be accepted on a rolling basis up until that date.

Open to research teams and aspiring entrepreneurs from the National Institutes of Health and other federal laboratories, the free program guides researchers in exploring the commercial potential of their inventions.

Through DC I-Corps, you will:

  • Learn how to assess the commercial value of life science technologies through a customer discovery process;
  • Work closely with six or more real-world advisors that have startup, venture capital, and technology commercialization experience over a five-week period; and
  • Come to a clear go or no-go decision regarding the commercial potential of your technology.

The program is geared towards innovations coming from medical / health / and life sciences. DC I-Corps builds upon the successful National Science Foundation (NSF) I-Corps program. The program is jointly offered by the University of Maryland, BioHealth Innovation, Inc., George Washington University, and Virginia Tech.

For more information, please visit www.dcicorps.org/nih-bhi-program-information/

Location and Program Dates: www.dcicorps.org/nih-program-dates/

To Apply: www.dcicorps.org/nih-bhi-cohort-application

back to top Back to top



Novartis, NEA join $188M gamble on China biotech fund – FierceBiotech

nea-logo

BVCF, a Shanghai-based life sciences investor, has closed its third fund with $188 million to back upstart biotechs on both sides of the Pacific focused on the booming Asian market. Dow Jones’ VentureWire and other media outlets reported that the backers to this fund include Novartis ($NVS), BlackRock, NEA and International Finance, which is gambling $20 million on the fund at a when time drug development activities in China continue to heat up.

BVCF sits on the crossroads of a relatively small but fast-growing area in biotech. U.S. and European biopharma companies have been looking for new ways to enter the Chinese drug market as the Big Pharma giants build out large new R&D operations in Asia and start linking up with academic groups. And the trend is spawning new joint ventures and company startups with in-licensed development projects.

back to top Back to top



GlaxoSmithKline joins a Big Pharma immuno-oncology R&D alliance – FierceBiotech

gsk-glaxo-vert-logo

Drug research is a small world, where the main players often intersect repeatedly as they take on new roles at different institutions. And MD Anderson’s new “moon shots” program on immuno-oncology is proving that maxim yet again as GlaxoSmithKline’s immunotherapy team suits up for the last big slot in an ambitious alliance of industry giants aimed at discovering some new products in the red-hot cancer R&D field.

GlaxoSmithKline ($GSK) is taking a berth next to teams from AstraZeneca ($AZN), Pfizer ($PFE) and Johnson & Johnson ($J&J). And the pact brings together two of the key players in the development of Yervoy, the pioneering anti-CTLA-4 immune checkpoint inhibitor which helped trigger one of the most frenetic development races the industry has seen.

back to top Back to top



TCM: Tech Wins in Maryland’s Legislative Session

tech-council-of-md-new-logo

The Tech Council of Maryland (TCM), Maryland’s largest technology trade association for life science and technology, today praised state lawmakers for advancing key priorities for the tech community during this year’s legislative session. The 2014 session concluded on Monday.

“We are encouraged to see Maryland lawmakers and the Administration come through on our biggest pro-growth priorities: stronger incentives for R&D, biotechnology, and cybersecurity,” said Phil Schiff, TCM’s CEO. “These industries are the catalysts for innovation and job growth in Maryland, and we are grateful to see so many policy makers in Annapolis recognize the pivotal role they will play in Maryland’s economic future.”

back to top Back to top



New Assay for Neisseria gonorrhoeae (GC) Testing Incorporates Real-Time PCR Technology

Becton-Dickinson-logo

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, announced today the CE mark and launch of the BD MAX™ GC rt PCR assay in Europe. The BD MAX GC rt PCR assay is an in vitro diagnostic test intended for testing Neisseria gonorrhoeae (GC) positive results from the BD ProbeTec™ GC Qx Amplified DNA Assay performed on the BD Viper™ System with XTR™ Technology. The assay may be used for detection of GC DNA in residual male or female urine specimens, or residual endocervical, vaginal or male urethral swab specimens that have tested positive for GC using the BD ProbeTec GC Qx Amplified DNA Assay.

back to top Back to top



Qiagen Expands Personalized Healthcare Pipeline

Qiagen

In a bid to expand its pipeline of Personalized Healthcare assays, Qiagen NV (QGEN – Snapshot Report) acquired an exclusive worldwide license for the calreticulin (CALR) biomarker from CeMM Vienna, the Research Center for Molecular Medicine of the Austrian Academy of Sciences.

Qiagen retains a strong pipeline of promising biomarkers under development for Personalized Healthcare tests pertaining to rheumatoid arthritis, lung cancer, colorectal cancer, glioblastoma, lymphoma and other cancers. Post acquisition of the license, Qiagen will develop a molecular diagnostic test for CALR mutations that will help healthcare providers to make more informed therapeutic decisions.

back to top Back to top



GSK Partners With MD Anderson For Cancer Immunotherapies Development

gsk-glaxo-vert-logo

The University of Texas MD Anderson Cancer Center announced its new collaboration with GlaxoSmithKline to advance development of cancer immunotherapies.

The collaboration will focus on the identification of new therapeutic approaches, evaluation of patient outcomes in clinical testing, and utilization of resulting information to develop drugs that recruit the body’s own immune system against cancer.

back to top Back to top



Request for Information (RFI): Human Cellular Models in CFTR Therapeutics for CF

nhlbi-logo-new.png

The National Heart, Lung, and Blood Institute (NHLBI) seeks feedback from the small business community regarding the current state of the science and commercial feasibility of using in vitro human cellular models as an experimental tool for predicting in vivo drug responses to cystic fibrosis transmembrane conductance regulator (CFTR)-directed therapeutics for Cystic Fibrosis (CF) lung disease at the individual level. Responses to this Request for Information (RFI) will assist NHLBI staff in assessing the value of the research in areas related to advancing precision medicine approaches to treatment.

back to top Back to top



NEA Launches New Installment of Design Mentorship Program “In the Studio” – Press Release – Digital Journal

nea-logo

New Enterprise Associates, Inc. (NEA), a leading global venture capital firm, today announced the kickoff of a second installment of its design mentorship program, In the Studio. Building on NEA’s successful 2013 program, In the Studio will be an intensive, two-week program for up to six design teams, developed and produced in collaboration with New York City-based product studio All Tomorrows, led by Albert Lee, and with Liz Danzico, founding chairperson of the Interaction Design program at New York City’s School of Visual Arts. Applications are now being accepted for the program, which will take place June 2nd through 17th, 2014.

Led by NEA Partner Dayna Grayson, the program evolved in response to a growing community of entrepreneurially minded designers, particularly in the New York City tech ecosystem. With design increasingly central in building successful consumer and enterprise applications, the program recruits talented designers with entrepreneurial or startup aspirations and provides mentorship, resources and opportunities to collaborate.

back to top Back to top



Historic release of data gives consumers unprecedented transparency on the medical services physicians provide and how much they are paid

DHHS

Historic release of data gives consumers unprecedented transparency on the medical services physicians provide and how much they are paid

Today, as part of the Obama administration’s work to make our health care system more transparent, affordable, and accountable, Health and Human Services (HHS) Secretary Kathleen Sebelius announced the release of new, privacy-protected data on services and procedures provided to Medicare beneficiaries by physicians and other health care professionals. The new data also show payment and submitted charges, or bills, for those services and procedures by provider.

back to top Back to top



In D.C., incubators expand – Work It, Richmond

washington-dc-mall-sxc

Fifty-four weeks after it opened, 1776 serves as a packed and noisy hub for Washington’s startup community.

Evan Burfield and Donna Harris founded the business incubator in January 2013, and 1776 moved into its 12th-floor offices, which are a 10-minute walk north of the White House, on April 1, 2013.

back to top Back to top



Why I’m excited about the promising future of medicine – Washington Post Blog

wadhwa-headshot

Health care is a misnomer for our medical system. It should be called sick care. Doctors, hospitals and pharmaceutical companies only make money when we are in bad health. If we could instead prevent illness and disease, it would turn the entire medical system on its head and increase the quality of our lives.

The good news is that technology is on its way to letting us do this. It is now moving so rapidly that within a decade the small handheld medical reader used by Dr. Leonard McCoy in Star Trek — the tricorder — will look primitive. We are moving into an era of data-driven, crowdsourced, participatory, genomics-based medicine. Just as our bathroom scales give us instant readings of our weight, wearable devices will monitor our health and warn us when we are about to get sick. Our doctors—or their artificial intelligence replacements—will prescribe medicines or lifestyle changes based on our full medical history, holistic self, and genetic composition.

back to top Back to top



New Report Reveals Growth Trajectories and Top Policy Factors Affecting Biopharmaceutical Innovation & Growth – MarketWatch

phrma-logo

Today the Pharmaceutical Research and Manufacturers of America (PhRMA) released a report that outlines two potential growth trajectories for the U.S. biopharmaceutical sector and the top policy factors that enable the industry to innovate and, in turn, contribute to the U.S. economy.

Developed by the Battelle Technology Partnership Practice, the report finds that coverage and payment policies, a well-functioning, science-based regulatory system and strong intellectual property (IP) protections drive U.S. leadership in biopharmaceutical innovation, and if negative trends in these key policy areas continue, jobs supported by the industry would decrease over the next decade. However, if reasonable pro-innovation policies are pursued, the U.S. biopharmaceutical sector stands to retain and add well over 300,000 jobs to the U.S. economy by 2021.

back to top Back to top



Children’s Hospital’s first Innovators Showcase touts healthy invention – BetaBoston

childrens-hospital-boston-logo

A less-invasive brain diagnostic test, a surface so slippery bacteria can’t stick to it, and a low-cost mylar wrap to help warm babies’ heads after surgery were three of the projects on display at Boston Children’s Hospital’s first-ever Innovators Showcase Friday.

The event is part of a larger push by Chief Innovation Officer Naomi Fried’s office to seek out innovators across the organization, support them with advice and sometimes money, and help guide them towards commercialization.

back to top Back to top



What should be a healthcare startup’s prize for good work? [Hint: It’s not necessarily money]

penn-medicine-logo

If you were to ask most early-stage companies what they’d consider to be a decent prize from a group of investors for a well pitched device or service, they’d probably say money. But at an entrepreneur forum at Penn Medicine, the rewards were as varied as the groups offering them. Venture capitalists, angel investors, accelerators and incubators each offered a different take on what a reward should look like.

Philadelphia has been working to build a better entrepreneur ecosystem to grow companies and stimulate job growth. As part of that trend, institutions are looking for ways to get more investors involved.

back to top Back to top


Subscribe
Forward

In This Issue

About BHI

BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.


The Hive Application Deadline

hive-logo

Apr 1-Aug 1
TEDMED 2014



FLC National Meeting

flc-national-meeting

April 21-23
Bethesda North Marriott



8th Annual Postdoc Conference and Career Fair

Postdoc Logo

April 24
Bethesda North Marriott Conference Center



ISPE-CBA & BioBuzz present – Vendor Night 2014

ispe-logo

April 30
The Universities at Shady Grove


BioHealth Job Opportunities


JHU Technology Transfer – Portfolio Director



Medimmune – Associate Scientist I/II



MedImmune – Intern


Newsletter designed and distributed by:


Gazetty.co


The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.



tedco-logo-2

Finalists Selected for TEDCO’s Fourth Annual ICE Awards – Tedco

By News Archive

tedco-logo-2

The Maryland Technology Development Corporation (TEDCO) announced today that nine finalists have been selected in the organization’s fourth annual ICE Awards. The awards program, which recognizes Innovation, Corporate Excellence and Entrepreneurship, will reward outstanding businesses and individuals from TEDCO’s diverse portfolio of more than 300 seed and early-stage companies. Winners will be announced on Thursday, May 15 from 8:30 am – 11:30 am during the awards ceremony at the Sheraton Columbia Town Center Hotel in Columbia, Md.  

“TEDCO’s portfolio companies encompass an incredibly diverse range of industries, technologies and innovations,” said Rob Rosenbaum, president and executive director of TEDCO. “We are pleased to announce this year’s ICE Awards finalists and congratulate them on their continued success in some of the fastest-growing and most competitive fields out there. Most importantly, we look forward to continuing to support leading Maryland innovators.”

Read More
jhu-umd-logos

Biomedical Engineering News – 2nd Annual JHU–UMD BMES Undergraduate Research Day

By News Archive

jhu-umd-logos

On Friday, March 28th, a contingent of Johns Hopkins University Depart­ment of Biomedical Engineering (JHU BME) undergraduate students and faculty visited the University of Maryland campus in College Park, Md. to participate in the second annual JHU–UMD Under­graduate Research Day with undergraduates from the University of Maryland’s Fischell Department of Bio­engineering (UMD BioE).

This event is organized by the two universities’ student Biomedical Engineering Society (BMES) chapters — under the leadership of chapter presidents Anvesh Annadanam (JHU BME), and Luke Peterken (UMD BioE).

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.